Management of Intrabony Defects using Hydroxyapatite/β-Tricalcium Phosphate Bone Substitute Alone or Combined with a Collagen Barrier: A Pilot Split-mouth Randomized Clinical Trial

1Shaleen Khetarpal, 2Unnati Pitale, 3Mishthu Solanki, 4Madhu S Ratre, 5Manish Verma, 6Ruchi Gulati

ABSTRACT

Aim: To determine the clinical efficacy of biphasic hydroxyapatite+β-tricalcium phosphate (HA/β-TCP) alone or in the presence of collagen membrane (CM) in the management of intrabony defects.

Materials and methods: Nineteen bilateral intrabony defects with an intrabony component ≥4 mm were selected and randomly allocated in a double-blind, split-mouth design to receive either HA/β-TCP+CM (test) or HA/β-TCP (control). Analytical parameters measured at baseline and 1 year after surgery included plaque index, gingival index, probing depth (PD), clinical attachment level (CAL), gingival recession (R), radiographic defect depth (RDD), and radiographic percentage bone fill (PBF).

Results: One year after therapy, the test treatment resulted in statistically higher PD reductions ($p<0.001$) and CAL gains ($p<0.001$) than the control one. In the test group, all sites (100%) gained at least 3 mm of CAL, whereas in the control group only 10 sites (53%) gained CAL of ≥3 mm. The mean radiographic PBF calculated at the end of 1 year was found to be 41.3 ± 20.6% for the test group and 30 ± 20.5% for the control group, with a significant ($p = 0.016$) improvement in the PBF for the former.

Conclusion: The present data appear to indicate that treatment with HA/β-TCP in combination with collagen barrier may result in higher clinical improvements than that achieved with HA/β-TCP alone.

Keywords: Collagen, Grafts, Guided tissue regeneration, Hydroxyapatite, Membrane.

How to cite this article: Khetarpal S, Pitale U, Solanki M, Ratre MS, Verma M, Gulati R. Management of Intrabony...
can improve the clinical results, is GTR. Collagen barriers have been extensively investigated in various GTR procedures over the years. It offers several advantages but its main disadvantage is that it tends to collapse in large defects if a broad base is not provided and the membrane is not supported. A bone graft placed under the CM may help support it.

As there is insufficient evidence regarding the use of HA and β-TCP in combination with collagen barrier, the following split-mouth, randomized, double-blind clinical study has been designed to evaluate the clinical efficacy of HA/β-TCP alone or in combination with a barrier membrane of type 1 collagen derived from bovine Achilles tendon in the management of intrabony defects.

MATERIALS AND METHODS

Subjects

Twelve patients (nine males and three females, aged 31–40 years, mean age 33.7 ± 3.12 months) having 19 bilateral intrabony defects in the premolar–molar area were selected from individuals seeking periodontal treatment at the institute hospital (Modern Dental College & Research Centre, Indore and Government College of Dentistry, Indore, India) between January 1, 2007 and October 1, 2017. A total of 38 sites were treated. All patients had a history of chronic periodontitis with advanced loss of periodontal support, characterized by periodontal PD of ≥ 6 mm, CAL > 4 mm, and radiographic evidence of alveolar bone loss. The selected defects exhibited depth of intrabony component ≥ 4 mm. All subjects were systemically healthy, cooperative, and understood the study protocol. A written consent (approved by the Ethics Committee of the Institute) of all the human subjects who participated in the study was obtained after the nature of the procedure and risks had been fully explained.

Presurgical Treatment

A complete case history was recorded and all subjects received an initial periodontal therapy including plaque control instructions, full-mouth scaling, root planing, and occlusal adjustment, where necessary. Plaque control instructions were repeated until patients achieved plaque scores and gingival index scores of ≤ 1 each. The enrollment of the bilateral sites by random allocation (a coin toss) to the intervention groups (HA/β-TCP+CM, i.e., test and HA/β-TCP, i.e., control) was performed by the operator (SK) performing the surgery. All assessments were performed by a masked calibrated examiner (HJD). Training and calibration were conducted prior to the start of the study to ensure intra- and extraradiner reproducibility. The calibration was done by examining a few patients and comparing with gold standard examiner (UP). All patients were also masked to the different treatment allocation.

Analytical Parameters

Full-mouth plaque score, gingival index, probing PD, R, and CAL were recorded at baseline and 1 year. All the measurements were recorded with a manual pressure-sensitive periodontal probe, calibrated at a force of 0.2 N with UNC-15 markings. Occlusal acrylic stents with longitudinal grooves were fabricated for all the patients to standardize the periodontal probe angulation and position. The cementoenamel junction (CEJ) was used as the fixed reference point. In cases where the CEJ was not clearly visible, the lower border of the groove on acrylic stent that covered the experimental tooth was used.

The intrabony defect depth (IDD) was measured during the surgery from the most coronal extension of bone crest to the deepest level of the defect. The bony defects were also classified as one-, two-, or three-wall defects depending on their topography in the vertical direction.

Radiographic Analysis

An intraoral periapical (IOPA) radiograph was taken of each selected site with long-cone paralleling technique using film-holding devices to measure the RDD. Radiographic measurements were obtained utilizing a film mount with millimeter grid scale. The grid scale lines are printed at 1 mm intervals with bold lines at 5 mm intervals. The developed IOPA film was inserted in the mount to measure the defect depth at baseline and after 1 year. Vertical linear distances between the CEJ and the apical most part of the defect were obtained by mounting the radiograph on the grid and counting the number of squares (each square = 1 × 1 mm). The radiographic PBF was also calculated for each defect. The percentage of change for the linear measurement radiographically was calculated as:

\[
PBF = \frac{\text{Preoperative Measurement} - \text{Postoperative Measurement}}{\text{Preoperative Measurement}} \times 100
\]

Surgical Procedure

Test Group (HA/β-TCP+CM)

After recording of the baseline parameters (Figs 1A and B), local anesthesia was administered and an access full-thickness flap was reflected. The osseous defect was debrided and their depth was measured and classified depending on the number of bony walls present (Fig. 1C).
Presuturing was done with 3-0 Mersilk and the defect was packed with the bone graft material, which was hydrated with saline (Fig. 1D). Care was taken not to overfill the osseous defects. The CM was trimmed (Fig. 1E) in such a way that it overlapped the alveolar bony walls of the defect by at least 2 mm. It was folded in half and passed interproximally beneath the interdental contacts. The dense smooth surface faced the soft tissue and the rough side faced the bone. It was applied over the defect and was held in place with moderate pressure. No sutures were used for stabilization of the membrane (Fig. 1F). The mucoperiosteal flaps were approximated and sutured to their original position using interdental interrupted sutures (Fig. 1G). The surgical site was dressed with a periodontal dressing, on the buccal and lingual aspects without application of excessive pressure interdentally. Figures 1H and I illustrate 1-year postoperative clinical and radiographic views of the treated site respectively.

Postoperative Care and Follow-up

Postoperative care and plaque control instructions were given and analgesics (a combination of ibuprofen 325 mg and paracetamol 400 mg) prescribed. Periodontal dressing and sutures were removed after 7 days postsurgery. The patients were recalled every 3 months for the first year postsurgery when they received full-mouth professional prophylaxis. A complete postoperative evaluation was performed of the test and control sites at the end of 1 year (Figs 3 and 4). The clinical and radiographic data obtained were tabulated and statistical analysis was carried out.

Statistical Analysis

Descriptive statistics were computed for each parameter recorded at baseline and 1 year postsurgery for both the groups. Student’s paired t-test was used to compare the data from the baseline to those at 1 year for each treatment group and between treatment groups at baseline and 1 year postsurgery. The level of significance of 0.05 was employed for all statistical comparisons.
Sample Size Calculation

Prior to the initiation of this study, power calculations performed indicated that a sample size of 17 evaluable sites was needed to detect a difference of 2.0 mm in change in attachment level with power of 80% and allowing α error of 0.05. The calculations were based on the assumptions that equal number of subjects would be allotted to the test and control groups and the primary outcome variable would be gain in clinical attachment (continuous), the standard deviation (SD) of which was around 2.0 mm (estimated from previous studies with similar inclusion/exclusion criteria). A total sample size of 19 was taken to compensate for any loss to follow-up.
Shaleen Khetarpal et al

RESULTS

All patients completed the study. Healing was uneventful in all treatment groups. Baseline defect characteristics of the test and control sites are presented in Table 1. At baseline, no differences in the initial depth of the intrabony defects were found between the two groups. Likewise, there was no difference in the distribution of one-, two-, and three-wall defects among the groups as illustrated in Table 2.

The clinical parameters at baseline and 1 year after treatment are presented in Table 3. The scores of hygiene indices in both groups remained low throughout the study period. At 1 year after therapy, the test group showed a reduction in the mean PD from 7.579 ± 1.953 to 2.684 ± 0.82 mm and a change in the mean CAL from 8.0 ± 1.795 to 3.316 ± 1.204 mm. In the control group, the mean PD was reduced from 6.789 ± 0.787 to 4.316 ± 0.946 mm and the mean CAL changed from 7.263 ± 0.733 to 5.000 ± 1.155 mm. The test treatment resulted in statistically higher PD reductions (p < 0.001) and CAL gains (p < 0.001) than the control one. In the test group, the RDD reduced from 5.842 ± 1.772 to 3.421 ± 1.502 mm with a mean radiographic defect fill of 2.421 mm at the end of 1 year, while for the HA/β-TCP group, RDD reduced from 5.000 ± 1.599 to 3.316 ± 1.003 mm with a mean defect fill of 1.684 mm. This difference was significant within the groups; however, between the groups it was not significant.

The frequency distribution of CAL gain for both treatment groups is shown in Table 4. In the test group, all sites (100%) gained at least 3 mm of CAL. In this group, a CAL gain of 3 to 4 mm was measured at 12 sites (63%), whereas at 7 sites (37%), the CAL gain was >5 mm. In the control group, no CAL gain occurred at two sites (11%), whereas at seven sites (36%), the CAL gain was only 1 to 2 mm. A CAL gain of 3 to 4 mm was measured in the remaining 10 defects (53%).

For the test group, the PBF scores ranged from 0.0 to 100% with a mean of 41.3% and for the control group it was between 0.0 and 60% with a mean of 30.0% (Table 5). When the mean PBF scores of both the treatment groups were compared at the end of 1 year, it was found to be

Table 1: Baseline defect characteristics of test and control sites expressed in mm (n = 19 for each group)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>PD (mm) (mean ± SD)</th>
<th>CAL (mm) (mean ± SD)</th>
<th>R (mm) (mean ± SD)</th>
<th>IDD (mm) (mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HA/β-TCP+CM</td>
<td>7.579 (±1.953)</td>
<td>8.000 (±1.795)</td>
<td>0.474 (±0.513)</td>
<td>4.579 (±0.769)</td>
</tr>
<tr>
<td>HA/β-TCP</td>
<td>6.789 (±0.787)</td>
<td>7.263 (±0.733)</td>
<td>0.526 (±0.697)</td>
<td>4.474 (±0.697)</td>
</tr>
</tbody>
</table>

Table 2: Distribution of the type of defects (n = 19 for each group)

<table>
<thead>
<tr>
<th>Type of defect</th>
<th>HA/β-TCP+CM group (No. of sites)</th>
<th>HA/β-TCP group (No. of sites)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Three-wall defects</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>Two-wall defects</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>One-wall defect</td>
<td>3</td>
<td>5</td>
</tr>
</tbody>
</table>

Figs 4A to D: Preoperative and postoperative radiographs of case 3. (A, B) Preoperative radiographs of test and control sites showing angular defects. (C, D) One-year postoperative radiographs of the test and control sites showing bone fill

Table 3: Clinical parameters at baseline and 1 year after treatment

<table>
<thead>
<tr>
<th>Treatment</th>
<th>PD (mm) (mean ± SD)</th>
<th>CAL (mm) (mean ± SD)</th>
<th>R (mm) (mean ± SD)</th>
<th>IDD (mm) (mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HA/β-TCP+CM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HA/β-TCP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 4: Frequency distribution of CAL gain

<table>
<thead>
<tr>
<th>Type of defect</th>
<th>HA/β-TCP+CM group (No. of sites)</th>
<th>HA/β-TCP group (No. of sites)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Three-wall defects</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>Two-wall defects</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>One-wall defect</td>
<td>3</td>
<td>5</td>
</tr>
</tbody>
</table>

Table 5: Mean PBF scores

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Mean PBF</th>
</tr>
</thead>
<tbody>
<tr>
<td>HA/β-TCP+CM</td>
<td>41.3%</td>
</tr>
<tr>
<td>HA/β-TCP</td>
<td>30.0%</td>
</tr>
</tbody>
</table>
statistically significant (p = 0.016) for the HA/β-TCP+CM group as compared with HA/β-TCP group, thereby indicating a significantly greater PBF for the former group.

DISCUSSION

The periodontal literature mentions a variety of bone substitutes being used; however, the search for the optimal bone graft continues. The bone graft used in the present study is a combination of HA and β-TCP in a ratio of 70/30. It has 90% interconnected porosity, i.e., when placed in the defect it occupies only 10% of the defect space leaving 90% space for regeneration. It has a particle size of 0.25 to 1 mm. A smaller particle or larger pore size may be preferred to allow more rapid bioabsorption, greater surface area, and increased osteogenesis.  

Hydroxyapatite and β-TCP individually have shown significant clinical improvements in grafted sites compared with non-grafted sites in controlled clinical studies. Animal studies have shown that β-TCP is compatible with host tissues and enhances bone deposition by triggering macrophages. The combination of HA and β-TCP with the resultant development of biphasic calcium phosphate has made it possible to control the resorbability of the material and at the same time maintain its osteoconductive property. Also, as it has no organic component, it is biocompatible, making it a safe material.

In the present study, the CM used is a bi-textured, resorbable, nonfriable membrane engineered from highly purified type 1 collagen derived from bovine Achilles tendon. Exogenous collagen is chemotactic for periodontal ligament fibroblasts and improves fibroblast migration and attachment through its scaffold-like
fibrillar structure. It also creates a thrombogenic surface that stimulates platelet attachment, which may accelerate fibrin and clot attachment. These biological properties of collagen may aid in periodontal reconstructive procedures. When bone grafts are used in conjunction with GTR, they serve as good space makers and create an environment favorable for clot stabilization. The combination therapy is an approach aimed at combining the positive aspects of different regenerative principles in order to possibly enhance the healing.

The purpose of this split-mouth randomized clinical trial was to compare the clinical efficacy of the HA/β-TCP bone substitute alone or combined with collagen barrier in the treatment of intrabony defects. To the best of our knowledge, there is no study in the literature comparing the effect of use of collagen barrier in combination with biphasic HA/β-TCP vs HA/β-TCP alone in the management of bilateral intrabony defects. Due to this lacunae in knowledge, comparisons were carried out with studies using similar bone substitute or with other bone graft-membrane studies.

One of the primary goals of periodontal therapy is to reduce the PD in order to limit the risk of local reinfec-
tion. At 1 year following therapy, the results of test group revealed a mean PD reduction of 4.895 mm and mean CAL gain of 4.684 mm while the control group showed mean PD reduction of 2.473 mm and mean CAL gain of 2.263 mm. The test group provided significantly (p < 0.001) greater PD reductions and CAL gains than the control sites. The results are in accordance with studies, which report that bone grafts in combination with membranes produce superior results.

The bone fill obtained was similar to or slightly less than other similar studies, but no definitive comparisons can be made due to the difference in bone graft material. The mean radiographic PBF calculated at the end of 1 year was 41.3% for the test group and 30% for the control group, with a statistically significant improvement for the former. The PBF is a more sensitive and reliable indicator of bone fill than defect depth as it shows amount of bone fill in relation to the initial depth of defect in terms of percentage without considering the discrepancy in the initial linear defect depth. Direct bone measurement, both linear and volumetric, by re-entry methods is frequently used as the primary endpoint variables in clinical trials of regenerative therapy. But a major disadvantage of this method is the need for a second surgical procedure to visualize the osseous defects; also it does not show the type of attachment that exists, i.e., long junctional epithelium or new attachment. To overcome this difficulty, radiographic monitoring of alveolar bone changes has been preferred in our study. Radiographic bone measurement is noninvasive, painless alternative to direct bone measurements.

The favorable results observed in this study may be due, in part, to the defect shape. In our study, the majority of the defects were three-walled. A high potential of three-walled defects for bone regeneration, irrespective of the treatment modality used, has been previously reported. According to Selvig et al. and Tonetti et al., the defects with greatest amounts of depth at baseline have greatest amounts of probing PD reductions, attachment gains, and bone fill.

The most reliable outcome variable for assessing periodontal regeneration is human histology. Because histologic specimens were not obtained in this study due to ethical considerations and patient management limitations, inferences about the quality of bone formation at any given time-point or the type of healing attachment gained cannot be made. Previous findings do indicate that the use of grafts or GTR or the combined use of both techniques may result in the formation of new histologic attachment.

However, there is no histologic evidence that synthetic graft materials support periodontal regeneration.

Another limitation of the present clinical study may lie in the fact that the sample size was small. Multiclinical trials with long-term analysis and larger sample sizes are required to determine the stability of the results. Ethical considerations and patient non-acceptance restricted direct bone measurements. The existence of an unknown bias cannot be excluded, although statistical analysis revealed that no significant difference in baseline parameters existed between the treatment groups. Nevertheless, attempts were made to minimize any bias as far as possible. Possible confounder like smoking was eliminated by selecting only nonsmokers in the study. The defect depth was standardized, and teeth exhibiting confounding factors, such as restorations in the defect area or furcation involvement, were excluded from the study.

REFERENCES

Collagen Barrier for Management of Intrabony Defects


